gms | German Medical Science

102. Jahrestagung der DOG

Deutsche Ophthalmologische Gesellschaft e. V.

23. bis 26.09.2004, Berlin

Pegaptanib (Macugen) as a VEGF-binding agent for the treatment of choroidal neovascularization in AMD (EOP1009)

Meeting Abstract

  • corresponding author F. Roth - Department of Ophthalmology, University of Bonn Medical Center
  • N. Eter - Department of Ophthalmology, University of Bonn Medical Center
  • A. Bindewald - Department of Ophthalmology, University of Bonn Medical Center
  • T. Krohne - Department of Ophthalmology, University of Bonn Medical Center
  • F. G. Holz - Department of Ophthalmology, University of Bonn Medical Center

Evidenzbasierte Medizin - Anspruch und Wirklichkeit. 102. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft. Berlin, 23.-26.09.2004. Düsseldorf, Köln: German Medical Science; 2004. Doc04dogSA.13.08

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/dog2004/04dog389.shtml

Veröffentlicht: 22. September 2004

© 2004 Roth et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Purpose of the study is to determine the effect of intravitreal injections of pegaptanib sodium on foveal thickening in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Furthermore to evaluate the relationship between foveal thickening and visual acuity. In a phase II prospective, randomized, double-masked, sham controlled, dose-ranging, multicenter trial a total of 135 patients with subfoveal choroidal neovascularization in AMD will be enrolled. Patients will be randomized in 3 groups, receiving 0.3 mg, 1mg Pegaptanib or sham injection. Treatment will be administered every 6 weeks for 3 injections and patients will be followed without treatment through 24 weeks. At week 24 patients will resume treatment every 6 weeks for the period of 1 year. Group 1 and 2 (0.3mg/eye and 1mg/eye) will continue on the same dose, group 3 will be re-randomized at week 24 to 0.3mg/eye or 1 mg/ eye Pegaptanib for the remainder of the study. Efficacy outcome measures are foveal thickness measured with OCT and ETDRS visual acuity.